HCLTECH
HCLTech, a leading global technology company, is joining governments, businesses and civil society from across the world at the World Economic Forum (WEF) 2023 in Davos to facilitate dialogue and collaboration for a sustainable planet and inclusive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005173/en/
HCLTech pavilion at Promenade66, Davos (Photo: Business Wire)
HCLTech is proud of its long-standing strategic partnership with the WEF. The HCLTech Pavilion at WEF 2023 showcases the company’s new brand identity and purpose of bringing together the best of technology and people to supercharge progress for clients, its people, communities and the planet.
Located at Promenade 66, 7270 Davos Platz, the HCLTech Pavilion is fully powered by green energy, underscoring the company’s commitment to a sustainable planet.
As part of HCLTech’s focus on diversity and gender equality, the company is hosting the UN Women’s Gender Equality Hub at its Pavilion. The Hub will feature daily video check-ins, pop-up panel discussions and fireside chats.
HCLTech’s leadership team will join and host global leaders at WEF in thought-provoking sessions around the Annual Meeting’s theme of “Cooperation in a Fragmented World” and discuss solutions to address the diverse crises facing the world.
Roshni Nadar Malhotra, Chairperson, HCLTech will join former U.S. Vice President Al Gore and other distinguished leaders at “Leading the Charge through Earth’s New Normal” - a session to discuss transformative solutions and global collaboration to build a more inclusive, prosperous and sustainable future. She will also join “The Aquapreneur Revolution” - a session hosted by Emma Benameur, Head of Impact and Engagement and Member of the WEF Executive Committee to announce the winners of The Global Freshwater Innovation Challenge under HCL Group and UpLink’s quest to find innovative solutions for freshwater conservation.
C Vijayakumar, CEO & Managing Director, HCLTech will share his vision at “Preparing One Billion People for Tomorrow’s Economy” - a session to discuss critical interventions needed to skill one billion people by 2030 in a world being rapidly transformed by technology. He will be joined by Saadia Zahidi, Managing Director, WEF and business leaders from Merck, Manpower Group and UBA Group.
In addition, Santhosh Jayaram, Global Head of Sustainability, HCLTech will spearhead the “Sustainability Dialogues with HCLTech” - a series of sessions with industry-leading business and thought leaders to engage in an open dialogue, focused on the most pressing agendas and topics around sustainability.
Srinivasan Seshadri, Corporate Vice President and Global Head of Financial Services, HCLTech will be part of “Operating Models in the Wake of Deglobalization” - a session on the growing need of businesses for innovative models to insulate them from the growing volatility in the global environment.
HCLTech CMO Jill Kouri will speak at “Generation Equality Pop Up, Role of Women in Climate Action” - a session that will include Kate Behncken, Corporate Vice President, Microsoft Philanthropies and Caitlin Kraft Buchman, Founder, CEO, Women@TheTable.
To learn more about HCLTech@WEF 2023 visit https://www.hcltech.com/world-economic-forum.
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December, 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005173/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom